Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

BioSpace Unveils Inaugural 40 Under 40 List, Highlighting Innovation and Leadership in Biopharma

BioSpace Unveils Inaugural 40 Under 40 List, Highlighting Innovation and Leadership in Biopharma

BioSpace has announced its first-ever 40 Under 40 list, recognizing young professionals who are making significant contributions to the biotech and pharmaceutical industries. The inaugural cohort includes CEOs, company founders, and executives from various disciplines, showcasing the depth of talent and innovation driving the sector forward.

NoahAI News10/8/2025
OXB Expands US Presence with $4.5M Acquisition of Viral Vector Plant from National Resilience

OXB Expands US Presence with $4.5M Acquisition of Viral Vector Plant from National Resilience

Oxford Biomedica (OXB), a UK-based cell and gene therapy manufacturer, has made a significant move to bolster its US operations by acquiring a viral vector plant in North Carolina from National Resilience for $4.5 million. This strategic purchase comes less than two months after OXB announced plans to expand its US footprint, supported by a recent equity raise of £60 million ($81 million).

NoahAI News10/8/2025
GLD Partners Launches Altagenics to Tackle Muscle-Wasting Diseases Using Heligenics' GigaAssay Platform

GLD Partners Launches Altagenics to Tackle Muscle-Wasting Diseases Using Heligenics' GigaAssay Platform

In a significant move that could reshape the landscape of muscle-wasting disease treatments, GLD Partners has announced the launch of Altagenics, a new biotech startup focused on developing first-in-class medicines for conditions such as sarcopenia and cachexia. The venture leverages Heligenics' cutting-edge GigaAssay platform, marking a strategic collaboration between the investment firm and the functional genomics company.

NoahAI News10/8/2025
Convatec Announces $1 Billion Investment in R&D Facilities Across US and UK

Convatec Announces $1 Billion Investment in R&D Facilities Across US and UK

Convatec, a leading provider of medical devices for chronic conditions management, has unveiled plans for a significant investment in research and development facilities in the United States and United Kingdom. The company aims to bolster its innovation capabilities and expand its market presence through a decade-long commitment totaling over $1 billion.

NoahAI News10/8/2025
GEMMABio Launches RareTx: A New Frontier in Gene Therapy for Ultra-Orphan Diseases

GEMMABio Launches RareTx: A New Frontier in Gene Therapy for Ultra-Orphan Diseases

In a bold move to address the unmet needs of patients with ultra-rare diseases, GEMMABio, founded by gene therapy pioneer James Wilson, M.D., Ph.D., has announced the launch of a new clinical-stage spinout company, Rare Therapeutics (RareTx). This development marks a significant step forward in the pursuit of genetic medicines for some of the most underserved patient populations worldwide.

NoahAI News10/8/2025
Atlantic Health and Saint Peter's Healthcare System Call Off Merger Plans Amid Shifting Healthcare Landscape

Atlantic Health and Saint Peter's Healthcare System Call Off Merger Plans Amid Shifting Healthcare Landscape

Atlantic Health System and Saint Peter's Healthcare System have abandoned their plans to merge, citing the rapidly evolving healthcare landscape as the primary reason for terminating the combination. The decision marks a significant setback for both New Jersey-based nonprofit healthcare providers, who had been working towards consolidation since early 2024.

NoahAI News10/8/2025
FDA Signals Flexibility for Rare Disease Gene Therapy Approval

FDA Signals Flexibility for Rare Disease Gene Therapy Approval

The U.S. Food and Drug Administration (FDA) has indicated a willingness to consider a more streamlined approval process for Lexeo Therapeutics' experimental gene therapy for Friedreich's ataxia, a rare neurodegenerative disorder. This development highlights the agency's evolving approach to gene therapies for rare diseases under new leadership.

NoahAI News10/8/2025
Encora Therapeutics Shakes Up Leadership as FDA Review Looms

Encora Therapeutics Shakes Up Leadership as FDA Review Looms

Encora Therapeutics, a Cambridge, Massachusetts-based company developing wearable devices for movement disorders, has announced a significant leadership change. Nadim Yared, formerly of CVRx, has been appointed as the new Chairman and CEO, replacing co-founder Daniel Carballo.

NoahAI News10/8/2025
Eli Lilly Calls for Urgent Improvements in Alzheimer's Diagnostic Testing Across Europe

Eli Lilly Calls for Urgent Improvements in Alzheimer's Diagnostic Testing Across Europe

Pharmaceutical giant Eli Lilly is urging European countries to make significant enhancements to their Alzheimer's disease diagnostic testing practices. This call to action comes shortly after the company received approval for its Alzheimer's therapy, Kisunla, in the European market.

NoahAI News10/8/2025
Boehringer Ingelheim's Jascayd Breathes New Life into Lung Fibrosis Treatment

Boehringer Ingelheim's Jascayd Breathes New Life into Lung Fibrosis Treatment

Boehringer Ingelheim has secured FDA approval for Jascayd (nerandomilast), marking the first new therapy for idiopathic pulmonary fibrosis (IPF) in over a decade. This breakthrough oral medication is poised to reshape the landscape of IPF treatment, offering new hope for patients battling this progressive and often fatal lung disease.

NoahAI News10/8/2025
MapLight Therapeutics Unveils $262M IPO Plans to Fund Schizophrenia Drug Development

MapLight Therapeutics Unveils $262M IPO Plans to Fund Schizophrenia Drug Development

MapLight Therapeutics, a California-based biotech company, has announced its intention to raise up to $262 million through an initial public offering (IPO) on the Nasdaq. The company plans to use the proceeds primarily to fund the development of its lead candidate, ML-007C-MA, a potential competitor to Bristol Myers Squibb's schizophrenia medication Cobenfy.

NoahAI News10/8/2025
US Government Invests $48M in Kernal Bio's mRNA CAR-T Program

US Government Invests $48M in Kernal Bio's mRNA CAR-T Program

The U.S. government has awarded up to $48 million to Kernal Bio and three sub-awardees to advance the development of an innovative in vivo mRNA-encoded CAR T-cell program. This significant investment, made through the Advanced Research Projects Agency for Health (ARPA-H), aims to support the progression of Kernal's early-stage program KR-402 through clinical development for multiple sclerosis and B-cell malignancies.

NoahAI News10/8/2025
«1...333435...67»